Charting the Course of Targeted α Therapy With First-in-Human, Postadministration Image-Guided Dosimetry and Response Assessment of 212Pb-VMT-α-NET in Metastatic Neuroendocrine Tumors

Abstract

Abstract 212Pb emerges as a compelling in vivo α-particle generator for targeted α therapy due to its favorable half-life (t 1/2 = 10.6 hours) aligning with the biological half-lives of small peptides and its potent α-particle emissions within the decay series. However, one of the challenges with 212Pb is to perform appropriate image-guided dosimetry. To date, all the data have been extrapolated from its imaging analog, 203Pb. We present the first-in-human posttherapy image-guided dosimetric estimates of a single cycle of 212Pb VMT-α-peptide, administered in a 41-year-old woman with an advanced grade 2 NET. The patient also demonstrated partial response on treatment.